Previous 10 | Next 10 |
home / stock / hnsbf / hnsbf news
2023-07-20 13:58:09 ET Hansa Biopharma AB (publ) (HNSBF) Q2 2023 Earnings Call Transcript July 20, 2023 08:00 AM ET Company Participants Soren Tulstrup - President and CEO Matthew Shaulis - CCO Donato Spota - SVP and CFO Conference Call Participants G...
2023-07-20 09:34:17 ET Hansa Biopharma press release ( OTCPK:HNSBF ): Q2 GAAP EPS of -SEK4.79. Revenue of SEK36.7M (+24.0% Y/Y). For further details see: Hansa Biopharma GAAP EPS of -SEK4.79, revenue of SEK36.7M
2023-04-20 14:50:06 ET Hansa Biopharma AB (publ) (HNSBF) Q1 2023 Earnings Conference Call April 20, 2023 08:00 ET Company Participants Søren Tulstrup - President & Chief Executive Officer Donato Spota - Senior Vice President & Chief Financial Officer ...
2023-04-20 03:47:06 ET Hansa Biopharma press release ( OTCPK:HNSBF ): Q1 GAAP EPS of -SEK 3.92. Revenue of SEK 24.2M (-20.1% Y/Y). For further details see: Hansa Biopharma GAAP EPS of -SEK 3.92, revenue of SEK 24.2M
2023-04-20 03:42:05 ET Hansa Biopharma ( OTCPK:HNSBF ) expects t otal Q1 revenue of SEK24.2M including SEK14.3M in product sales and SEK9.9M in revenue recognition mainly under the agreement with Sarepta. Appointed Matthew Shaulis as Chief Commercial Officer ...
Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...
Hansa Biopharma AB (publ) (HNSBF) Q4 2022 Earnings Conference Call February 02, 2023, 08:00 AM ET Company Participants Søren Tulstrup - President and CEO Donato Spota - SVP and CFO Conference Call Participants Gonzalo Attali - ABG Sundal Collier Zoe Ka...
The following slide deck was published by Hansa Biopharma AB (publ) in conjunction with their 2022 Q4 earnings call. For further details see: Hansa Biopharma AB (publ) 2022 Q4 - Results - Earnings Call Presentation
Hansa Biopharma press release ( OTCPK:HNSBF ): Q4 GAAP EPS of -SEK 3.19. Revenue of SEK 31M (+101.3% Y/Y). Cash runway extended into 2025. For further details see: Hansa Biopharma GAAP EPS of -SEK 3.19, revenue of SEK 31M
Hansa Biopharma AB (HNSBF) Q3 2022 Earnings Conference Call October 20, 2022 8:00 AM ET Company Participants Soren Tulstrup - President and Chief Executive Officer Donato Spota - Senior Vice President, Chief Financial Officer Conference Call Participants ...
News, Short Squeeze, Breakout and More Instantly...
Hansa Biopharma AB Company Name:
HNSBF Stock Symbol:
OTCMKTS Market:
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...
Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...
The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients PR Newswire Idefirix ® becomes the first and only product recommended by SMC...